Exact Sciences, Takeda & more: 4 GI company key notes

Here are four updates from gastroenterology companies from the past week:

The Royal Court of Jersey sanctioned Shire's proposed acquisition of Takeda Pharmaceuticals.

Exact Sciences expects to post fourth quarter 2018 revenues between $142.5 million to $143.5 million, a 64 percent year-over-year increase.

EnteraSense secured $4 million in funding for its gastrointestinal tract bleed-detecting capsule.

Landos Biopharma reported results from its phase 1 trial of BT-11, an ulcerative colitis and Crohn's disease treatment.

More articles on gastroenterology:
5 thoughts on Cologuard, gastroenterology's future & the tax threatening Connecticut ASCs from Dr. Charles Adelmann
Landos' IBD drug well-tolerated — 6 study insights
EnteraSense secures $4M in funding for bleed-detecting GI tract capsule — 4 insights

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Top 40 Articles from the Past 6 Months